A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2017
Price : $35 *
At a glance
- Drugs Lixisenatide (Primary) ; Insulin glargine; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 13 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.